Drugs.com - Clinical Trials

Cantargia's Nadunolimab Antibody Awarded Fast Track Designation by FDA

June 11, 2025 - Cantargia (Cantargia AB (publ); NASDAQ Stockholm: CANTA), today announced that the U.S. Food and Drug Administration (FDA) has granted nadunolimab, Cantargia's anti-IL1RAP antibody, Fast Track Designation (FTD) for the treatment of...

Jun 14, 2025 - 03:00
 0
Cantargia's Nadunolimab Antibody Awarded Fast Track Designation by FDA
June 11, 2025 - Cantargia (Cantargia AB (publ); NASDAQ Stockholm: CANTA), today announced that the U.S. Food and Drug Administration (FDA) has granted nadunolimab, Cantargia's anti-IL1RAP antibody, Fast Track Designation (FTD) for the treatment of...
Read More

Tags:

Previous Article

Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pa...

Next Article

A No Kings Day Demand For Climate Action And Democracy Protections

Related Posts

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

May 12, 2025  0

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Merck Announces Positive Topline Results From the First...

Jun 10, 2025  0

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

Vividion Therapeutics Doses First Patient in Phase I St...

May 12, 2025  0